Efficacy of mesenchymal stromal cells in the treatment of type 1 diabetes: a systematic review.
Cell Tissue Bank
; 25(2): 663-676, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38383908
ABSTRACT
To investigate the efficacy of mesenchymal stromal cells in the treatment of type 1 diabetes. Articles about the effects of mesenchymal stromal cells for T1D were retrieved in PubMed, Web of Science, Embase, and the Cochrane Library databases up to July 2023. Additional relevant studies were manually searched through citations. HbA1c, FBG, PBG, insulin requirement and C-peptide were assessed. The risk of bias was evaluated with the ROB 2.0 and ROBINS-I tools. Six RCTs and eight nRCTs were included. Of the 14 studies included, two evaluated BM-MSCs, three evaluated UC-MSCs, five evaluated AHSCT, two evaluated CB-SCs, and two evaluated UC-SCs plus aBM-MNCs. At the end of follow-up, ten studies found that mesenchymal stromal cells improved glycemic outcomes in T1D, while the remaining four studies showed no significant improvement. Findings support the positive impacts observed from utilizing mesenchymal stromal cells in individuals with T1D. However, the overall methodological quality of the identified studies and findings is heterogeneous, limiting the interpretation of the therapeutic benefits of mesenchymal stromal cells in T1D. Methodically rigorous research is needed to further increase credibility.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Mesenchymal Stem Cell Transplantation
/
Diabetes Mellitus, Type 1
/
Mesenchymal Stem Cells
Limits:
Humans
Language:
En
Journal:
Cell Tissue Bank
Journal subject:
HISTOLOGIA
/
TRANSPLANTE
Year:
2024
Document type:
Article
Affiliation country:
China
Country of publication:
Netherlands